Bayer's Ask Bio unit starts Phase II heart failure gene therapy

Bayer SE subsidiary Asklepios BioPharmaceutical Inc. (AskBio) has started Phase II testing of AB-1002 (NAN-101) in patients with congestive heart failure. 

AMPLY Discovery Ltd bags £1.4m funding to tackle complex diseases

Belfast-based techbio company<b>&nbsp;</b>AMPLY Discovery Ltd announced today will make use of a £1.4m in grant funding to advance its AI-based drug discovery platform.

EU parliament votes in favour of New Genome Techniques

The European Parliament adopted its position for negotiations with Member States on the Commission's proposal on new genomic techniques (NGTs) in favour for using CRISPR/Cas as a new but now […]

EU parliament backs deregulation of New Genome Techniques

After two &quot;Yes&quot;-votes in the European Parliament’s AGRI and ENVI committees, MEPs confirmed the European Commissions draft Regulation on New Genomic Technologies in plant breeding.<br />&nbsp;<br /><br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<br /><br […]

Jazz Pharmaceiticals licences KRAS blocker from Redx Pharma

Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.<br /><br />

Jazz Pharmaceuticals licences KRAS blocker from Redx Pharma

Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.<br /><br />